Following a period of relative exemption from escalating trade tensions, the global generic pharmaceutical industry is now facing the prospect…
Read More
Ionis Pharmaceuticals and Recordati Forge Global Partnership for Zilganersen in Alexander Disease
Ionis Pharmaceuticals has forged a significant global licensing agreement with Recordati, a prominent international pharmaceutical company, granting Recordati exclusive rights…
Read More
Jazz Pharmaceuticals and AbCellera Forge Strategic Alliance to Pioneer Novel T-cell Engaging Antibodies for Gastrointestinal and Solid Tumors
Jazz Pharmaceuticals and AbCellera have announced a significant preclinical research, option, and license agreement, poised to accelerate the discovery and…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
Arna Pharma and Slate Run Pharmaceuticals Forge Strategic Joint Venture to Accelerate Pharmaceutical Product Commercialization in the US Market
Arna Pharma and Slate Run Pharmaceuticals have finalized a significant joint venture (JV), establishing a new specialized pharmaceutical entity poised…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read MoreYOU MAY HAVE MISSED
